Har­vard's Gre­go­ry Ver­dine has big am­bi­tions for his minipro­tein 'braces' — and now $107M to guide them to the clin­ic

Har­vard sci­en­tist Gre­go­ry Ver­dine’s mis­sion has al­ways been clear: drug the un­drug­gable. He’s now one step clos­er, with $107 mil­lion in the bank to bring a new class of drugs to the clin­ic — and he isn’t rul­ing out an IPO.

Since launch­ing Fog­Phar­ma in 2016, Ver­dine and his crew have been hard at work on a new kind of ther­a­peu­tic class that com­bines the cell-pen­e­trat­ing ca­pac­i­ty of small mol­e­cules with the tar­get-en­gag­ing tenac­i­ty of bi­o­log­ics. The re­sult is what he calls CPMPs, or cell-pen­e­trat­ing minipro­teins.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER